|
|
|
|
Apatinib Mesylate |
|
Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
| |
|
|
|
Belzutifan |
|
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
2 |
| |
|
|
|
Bezuclastinib |
|
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors |
5 |
| |
|
|
|
Bezuclastinib plus Sunitinib |
|
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
3 |
| |
|
|
|
ctDNA plus Sunitinib or Regorafenib |
|
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST |
2 |
| |
|
|
|
DCC-3009 |
|
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) |
1/2 |
| |
|
|
|
DCC-3116 + Ripretinib |
|
A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies |
1/2 |
| |
|
|
|
deepGeneAI-001 + Sintilimab |
|
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment (PCV-GSTT) |
1 |
| |
|
|
|
HQP1351 |
|
A Study of HQP1351 (Olverembatinib) in Patients With GIST or Other Solid Tumors |
1 |
| |
|
|
|
Imatinib |
|
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
2 |
| |
|
|
|
Imatinib |
|
Imatinib TDM (Therapeutic Drug Monitoring) in GIST |
2 |
| |
|
|
|
Imatinib |
|
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01) |
2 |
| |
|
|
|
Imatinib |
|
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk |
2 |
| |
|
|
|
Imatinib + Atezolizumab |
|
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST) |
2 |
| |
|
|
|
Imatinib + Sunitinib + Regorafenib |
|
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure |
|
| |
|
|
|
KQB198 + Imatinib |
|
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) |
2 |
| |
|
|
|
MRTX1719 |
|
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
1/2 |
| |
|
|
|
NN3201 |
|
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit |
1 |
| |
|
|
|
Olverembatinib |
|
A Study of Olverembatinib in SDH-deficient GIST. (POLARIS-3) |
3 |
| |
|
|
|
Paclltaxel |
|
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
2 |
| |
|
|
|
Pemigatinib |
|
PEMIGIST: Phase 2 Study of Pemigatinib (INCB054828) in the Treatment of Patients With Advanced SDH-deficient Gastrointestinal Stromal Tumor (GIST) |
2 |
| |
|
|
|
Regorafenib + Avelumab |
|
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) |
1/2 |
| |
|
|
|
Regorafenib + Envafolimab |
|
A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment |
2 |
| |
|
|
|
Ripretinib |
|
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST |
NA |
| |
|
|
|
Ripretinib |
|
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy |
|
| |
|
|
|
Rivoceranib + Paclitaxel |
|
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor |
2 |
| |
|
|
|
Surgery |
|
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis |
|
| |
|
|
|
Temozolomide |
|
The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST) |
2 |
| |
|
|
|
Velzatinib |
|
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3) |
3 |
| |
|
|
|
Velzatinib |
|
Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) |
3 |
| |
|
|
|
Ziftomenib + Imatinib |
|
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
1 |
| |
|
|
|